List view / Grid view
A study by NYU Langone Medical Centre researchers adds to growing evidence that multiple courses of commonly used antibiotics may have a significant impact on children's development.
24 June 2015 | By Victoria White
Researchers have pinpointed a critical differentiator that separates the effects of bactericidal and bacteriostatic antibiotics: cellular respiration...
23 June 2015 | By Victoria White
Data presented at ASCO 2015 suggests that the Opdivo/Yervoy combination of immunotherapies to treat metastatic melanoma will shape the therapeutic landscape...
18 June 2015 | By Victoria White
A new study shows that the antibiotic azithromycin, often prescribed to cure common infections, kills many multidrug-resistant bacteria very effectively...
4 June 2015 | By Victoria White
Blaze Bioscience has announced open enrollment for the first clinical study of Tumour Paint BLZ-100 in children with brain cancer...
2 June 2015 | By kdm communications
Syrris, a world leader in chemistry product innovation, has launched the Atlas Nanoparticle System for the automated synthesis of quantum dots...
2 June 2015 | By Victoria White
Amgen and Roche are to collaborate on a study to evaluate talimogene laherparepvec in combination with atezolizumab in patients with cancer...
28 May 2015 | By Victoria White
Seres Therapeutics has enrolled and dosed the first patient in its Phase 2 clinical study of SER-109 in recurrent CDI in adults...
26 May 2015 | By Victoria White
A genetically engineered herpes virus, T-VEC, can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action...
14 May 2015 | By Victoria White
Roche has announced interim results from a global, randomised Phase II study (POPLAR) of MPDL3280A in people with previously treated NSCLC...
14 May 2015 | By Victoria White
Jim O’Neill’s Review on Antimicrobial Resistance sets out proposals to overhaul the global antibiotics pipeline over the next ten years...
12 May 2015 | By Victoria White
Inovio Pharmaceuticals has initiated a Phase I trial to evaluate safety, tolerability and immune responses of its Ebola DNA immunotherapy...
27 April 2015 | By Victoria White
Three posters on the Extended Spectrum Pleuromutilins (ESP) Programme and one poster on lefamulin were presented at ECCMID 2015...
In Issue #2 2015: Outsourcing, Drug pricing reforms, Stem Cells in-depth focus, Microbiology series, Environmental monitoring, LC-MS in-depth focus, Manufacturing solutions, PAT series and much more...
20 April 2015 | By Victoria White
The first patient has been dosed in a Phase 1 clinical trial of CM-24, a first-in-class immunomodulatory mAb for the treatment of various types of cancers...
